Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

11.0K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

690
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
690
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.5K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.5K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

591
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
591
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.6K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.6K
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

621
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
621

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Peptide Marriages: Modular Assembly of Multi-Agonist Therapeutics.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Response.

Gastrointestinal endoscopy·2026
Same author

Multicomponent Stapling of Glucagon-Like Peptide-1 Enables Receptor-Guided PROTAC Delivery.

Angewandte Chemie (International ed. in English)·2026
Same author

Boosting peptide half-life: enabling efficient generation of Fc-peptide conjugates.

Chemical science·2026
Same author

Endoscopic Diagnosis and Treatment for Superficial Non-Ampullary Duodenal Epithelial Tumors.

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society·2026
Same author

On-resin assembly of cysteine-reactive linkers for controlled site-selective antibody bioconjugation.

Nature protocols·2026

Related Experiment Video

Updated: Feb 11, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K

Second-generation CK2α inhibitors targeting the αD pocket.

Jessica Iegre1, Paul Brear2, Claudia De Fusco1,3

  • 1Department of Chemistry , University of Cambridge , CB2 1EW , Cambridge , UK .

Chemical Science
|May 8, 2018
PubMed
Summary

A novel protein kinase CK2 inhibitor, CAM4712, binds outside the active site for improved efficacy. This second-generation drug offers advantages over previous inhibitors, enhancing cell cycle regulation and anti-apoptotic strategies.

More Related Videos

A Mouse Model of the Cornea Pocket Assay for Angiogenesis Study
06:13

A Mouse Model of the Cornea Pocket Assay for Angiogenesis Study

Published on: August 18, 2011

16.4K
Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors
08:14

Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors

Published on: October 28, 2014

13.3K

Related Experiment Videos

Last Updated: Feb 11, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K
A Mouse Model of the Cornea Pocket Assay for Angiogenesis Study
06:13

A Mouse Model of the Cornea Pocket Assay for Angiogenesis Study

Published on: August 18, 2011

16.4K
Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors
08:14

Efficient iPS Cell Generation from Blood Using Episomes and HDAC Inhibitors

Published on: October 28, 2014

13.3K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Drug Discovery

Background:

  • Protein kinase CK2 (Casein kinase 2) is crucial for cell cycle regulation and inhibiting apoptosis.
  • Developing ATP-non-competitive CK2 inhibitors is a promising strategy due to conserved ATP binding sites across kinases.
  • Previous research identified CAM4066, a CK2 inhibitor binding to a pocket adjacent to the active site.

Purpose of the Study:

  • To develop and characterize a novel CK2α inhibitor that binds entirely outside the ATP-binding site.
  • To improve upon the properties of the first-generation inhibitor CAM4066.
  • To assess the efficacy and cellular permeability of the new inhibitor.

Main Methods:

  • Design and synthesis of a second-generation CK2α inhibitor (CAM4712).
  • Biochemical assays to determine in vitro kinase inhibition (IC50).
  • Cell-based assays to measure inhibition of cell proliferation (GI50).
  • Comparative analysis of CAM4712 with CAM4066 regarding chemical properties and biological activity.

Main Results:

  • CAM4712, a novel CK2α inhibitor, binds exclusively outside the ATP-binding site.
  • CAM4712 exhibits improved characteristics compared to CAM4066, including fewer rotatable bonds, absence of protease-susceptible amide groups, and enhanced cellular permeability.
  • No prodrug strategy was required for cellular uptake of CAM4712.
  • CAM4712 demonstrated consistent inhibition of kinase activity (IC50) and cell proliferation (GI50), indicating effective cellular activity.

Conclusions:

  • CAM4712 represents a significant advancement in CK2 inhibitor development.
  • Its unique binding mode and improved physicochemical properties make it a promising candidate for therapeutic applications targeting CK2.
  • This study validates the strategy of targeting allosteric sites for kinase inhibition.